Menu
Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1
Poly(d,l-lactide-co-glycolide)–chitosan composite particles for the treatment of lung cancer
Authors Arya N, Katti D
Received 25 November 2014
Accepted for publication 22 January 2015
Published 16 April 2015 Volume 2015:10(1) Pages 2997—3011
DOI https://doi.org/10.2147/IJN.S78120
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Thomas J. Webster
Neha Arya, Dhirendra S Katti
Department of Biological Sciences and Bioengineering, Indian Institute of Technology – Kanpur, Kanpur, Uttar Pradesh, India
Abstract: Tumor heterogeneity makes combination chemotherapy one of the preferred modes of treatment regimens. In this work, sequential exposure of two anticancer agents, paclitaxel (Tx) followed by topotecan (TPT), was shown to have a synergistic effect on non-small cell lung cancer (NSCLC) cell line, NCI-H460. In order to improve patient compliance, the aforementioned concept was translated into a drug delivery system comprising of poly(d,l-lactide-co-glycolide) (PLGA)–chitosan composite particles. TPT-containing chitosan micro-/nanoparticles were prepared by the facile technique of electrospraying and encapsulated within PLGA microparticles using emulsion-solvent evaporation technique for delayed release of TPT. The formulation containing Tx- and TPT-loaded composite particles demonstrated synergism when exposed to NCI-H460 cellular aggregates (tumoroids) generated in vitro. Overall, the results of this study demonstrated the potential of the formulation containing Tx and PLGA–chitosan (TPT-loaded) composite particles for the treatment of lung cancer.
Keywords: drug delivery system, solid tumor, paclitaxel, topotecan, sequential administration
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.